EP Patent

EP3592732A1 — Manufacture of a crystalline pharmaceutical product

Assigned to Orion Oyj · Expires 2020-01-15 · 6y expired

What this patent protects

The present invention relates to crystalline particles of N-(( S )-l-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1 H-pyrazole-3-carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m 2 /g, preferably from about …

USPTO Abstract

The present invention relates to crystalline particles of N-(( S )-l-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1 H-pyrazole-3-carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m 2 /g, preferably from about to about 15 m 2 /g, and to the method for the preparation of such particles. Compound (I) is a potent androgen receptor (AR) modulator which is useful as a medicament for example in the treatment of prostate cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3592732A1
Jurisdiction
EP
Classification
—
Expires
2020-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.